Tissue Repair & Recovery

ARA-290 (Cibinetide)

Also known as Cibinetide · Erythropoietin-derived peptide · Innate repair receptor agonist

Clinically studiedSubcutaneous injectionIntravenous infusion (trial settings)Investigational drug, not FDA-approved; holds FDA Orphan Drug and Fast Track designations for sarcoidosis-associated neuropathic pain. Multiple Phase 2 trials completed.

ARA-290, also called cibinetide, is a synthetic 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin. It is designed to activate the innate repair receptor to reduce inflammation and protect cells without stimulating red-blood-cell production. It has the most formal clinical-trial base in this category, having been evaluated in randomized, placebo-controlled Phase 2 studies, most notably in sarcoidosis-associated small-fiber neuropathy, where it was associated with increased corneal nerve fiber measures and reduced neuropathic pain.

Studied / used for

Studied in randomized Phase 2 clinical trials for sarcoidosis-associated small-fiber neuropathy
Investigated for neuropathic pain and nerve fiber regeneration
Investigated for metabolic measures in type 2 diabetes
Studied for tissue protection and anti-inflammatory effects

Commonly reported side effects

Injection-site reactions
Generally reported as well tolerated in trials
Reported not to raise red-blood-cell count, unlike erythropoietin

Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds